NEW YORK (GenomeWeb News) – Cellumen will partner with the Alzheimer’s Drug Discovery Foundation to develop a cellular model that could be used in Alzheimer’s treatments, the company said today.
 
Pittsburgh-based Cellumen plans to use its Cellular Systems Biology technology to develop a panel of assays and biosensors of protein interactions in order to find targets and pathways involved in the disease. This technology could allow researchers to conduct more clinically relevant drug screening, the company believes.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.